Single agent therapies have demonstrated efficacy with some well-known driver alterations, such as Vemurafenib with BRAF V600E mutations in melanoma,31 Erlotinib with EGFR exon 19 deletions in non-small cell lung cancer,32 or Imatinib with BCR-ABL1 fusions in chronic myeloid leukemia,33 leading to FDA approval. This evidence concerns the gene EGFR and non-small cell lung carcinoma.